From Adversity to Billionaire: Dr. Trisha Bailey’s Story Inspires a New Generation of Leaders

As Black History Month shines a spotlight on leaders who have shaped history and inspired generations, Dr. Trisha Bailey's story stands tall as a modern testament to Black excellence, perseverance, and legacy. A self-made billionaire, philanthropist, and visionary, Dr. Bailey's journey-captured in her bestselling memoir Unbroken-offers inspiration for all who dare to dream beyond adversity. […]

RDDT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Reddit, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Reddit, Inc. ("Reddit" or "the Company") (NYSE:RDDT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

DDD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that 3D Systems Corporation Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against 3D Systems Corporation ("3D Systems" or "the Company") (NYSE:DDD) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

RCKT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

FINAL REMINDER FTRE DEADLINE: Bronstein, Gewirtz and Grossman, LLC Announces that Fortrea Holdings, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Alto Neuroscience, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or "the Company") (NYSE:ANRO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

NANO Nuclear Selected for Inclusion in the Solactive Global Uranium & Nuclear Components Total Return Index, Qualifying It for Inclusion in the Prominent Global X Uranium ETF (“URA”)

(NASDAQ:NNE), With over $4 billion in net assets, the Global X Uranium ETF is the world's preeminent ETF providing investors broad exposure to companies involved in uranium mining and the production of nuclear components New York, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a

Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights

(TSX:MDNA),(OTC US:MDNAF),(Other OTC:MDNAF), Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated with other competing therapies in similar checkpoint resistant tumor types A patient with pancreatic cancer and a melanoma

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

(NASDAQ:BTAI), Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced completion of

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

(TSX:PYR),(OTC US:PYRGF),(Other OTC:PYRGF),(Frankfurt:8PY1), MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, today announces that

Scroll to Top